How were new medicines discovered?
- PMID: 21701501
- DOI: 10.1038/nrd3480
How were new medicines discovered?
Abstract
Preclinical strategies that are used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biologic-based approaches. To investigate whether some strategies have been more successful than others in the discovery of new drugs, we analysed the discovery strategies and the molecular mechanism of action (MMOA) for new molecular entities and new biologics that were approved by the US Food and Drug Administration between 1999 and 2008. Out of the 259 agents that were approved, 75 were first-in-class drugs with new MMOAs, and out of these, 50 (67%) were small molecules and 25 (33%) were biologics. The results also show that the contribution of phenotypic screening to the discovery of first-in-class small-molecule drugs exceeded that of target-based approaches - with 28 and 17 of these drugs coming from the two approaches, respectively - in an era in which the major focus was on target-based approaches. We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development.
Similar articles
-
The discovery of first-in-class drugs: origins and evolution.Nat Rev Drug Discov. 2014 Aug;13(8):577-87. doi: 10.1038/nrd4336. Epub 2014 Jul 18. Nat Rev Drug Discov. 2014. PMID: 25033734 Review.
-
Phenotypic screens as a renewed approach for drug discovery.Drug Discov Today. 2013 Nov;18(21-22):1067-73. doi: 10.1016/j.drudis.2013.07.001. Epub 2013 Jul 9. Drug Discov Today. 2013. PMID: 23850704 Free PMC article. Review.
-
The contribution of mechanistic understanding to phenotypic screening for first-in-class medicines.J Biomol Screen. 2013 Dec;18(10):1186-92. doi: 10.1177/1087057113501199. Epub 2013 Aug 27. J Biomol Screen. 2013. PMID: 23983234
-
The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules.Molecules. 2019 Feb 23;24(4):809. doi: 10.3390/molecules24040809. Molecules. 2019. PMID: 30813407 Free PMC article. Review.
-
The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules.Molecules. 2020 Feb 9;25(3):745. doi: 10.3390/molecules25030745. Molecules. 2020. PMID: 32050446 Free PMC article. Review.
Cited by
-
Whole-organism screening for gluconeogenesis identifies activators of fasting metabolism.Nat Chem Biol. 2013 Feb;9(2):97-104. doi: 10.1038/nchembio.1136. Epub 2012 Dec 2. Nat Chem Biol. 2013. PMID: 23201900 Free PMC article.
-
Recent advances in phenotypic drug discovery.F1000Res. 2020 Aug 7;9:F1000 Faculty Rev-944. doi: 10.12688/f1000research.25813.1. eCollection 2020. F1000Res. 2020. PMID: 32850117 Free PMC article. Review.
-
Constellation pharmacology: a new paradigm for drug discovery.Annu Rev Pharmacol Toxicol. 2015;55:573-89. doi: 10.1146/annurev-pharmtox-010814-124551. Annu Rev Pharmacol Toxicol. 2015. PMID: 25562646 Free PMC article. Review.
-
Proteome-Wide Fragment-Based Ligand and Target Discovery.Isr J Chem. 2023 Mar;63(3-4):e202200098. doi: 10.1002/ijch.202200098. Epub 2023 Feb 8. Isr J Chem. 2023. PMID: 38213795 Free PMC article.
-
Forward chemical genetics in yeast for discovery of chemical probes targeting metabolism.Molecules. 2012 Nov 5;17(11):13098-115. doi: 10.3390/molecules171113098. Molecules. 2012. PMID: 23128089 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical